For the first time ever, Lumito will have its own booth at a pathology congress. Booth number 79 has been booked for the European Congress of Pathology, which will take place in Basel from 3-7 September.
"We are now ready to expose our product at one of Europe's busiest trade fairs for pathologists and other professionals in the industry. For the company, this represents a milestone achieved and we are all excited to show our solution. Now we are leaving the development phase behind and enter the commercialization phase", comments CEO Mattias Lundin who will represent Lumito at the congress with a team of four colleagues from Sales & Marketing.
Lumito's innovative technology enables significantly improved tissue diagnostics that will help healthcare providers meet the demands for safe tissue diagnostics in personalised healthcare.
The ambition is to launch the first product in research laboratories in the latter part of 2022. Knowledge and experience from the research laboratories will be used when the product is next adapted to the clinical environment, while the company expects to generate revenue. According to the business model, the scanner will be sold as a capital good and the reagents as consumables, which generate recurring revenue.
Briefly about the solution
The solution consists of a whole slide imaging scanner (WSI), which is an optical analysis instrument, which together with Lumito's UCNP (Upconverting Nano Particles) based staining liquids for various disease markers (antibodies) enables pathologists to take digital images of tissues. The scanner may also capture images of traditionally stained tissue samples (hematoxylin staining and immunohistochemistry).
For further information, please contact:
Lumito specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalized healthcare. The technology enables higher contrast images where unimportant background information is sorted out, making it easier for pathologists to find cancer indications. The technology, based on Up Converting Nano Particles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shorter analysis times. The method has several potential applications, but Lumito has chosen to focus primarily on digital pathology. The company is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Centre. www.lumito.se
The share is traded on NGM Nordic SME, under the name LUMITO and Mentor is Mangold Fondkommission, phone: +46 (8) 5030 1550 and email, firstname.lastname@example.org.